European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.

Autor: Rack KA; GenQA, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK., van den Berg E; Department of Genetics University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Haferlach C; MLL-Munich Leukemia Laboratory, Munich, Germany., Beverloo HB; Department of Clinical Genetics, Erasmus MC, University medical center, Rotterdam, The Netherlands., Costa D; Hematopathology Section, Hospital Clinic, Barcelona, Spain., Espinet B; Laboratori de Citogenètica Molecular, Servei de Patologia, Grup de Recerca,Translacional en Neoplàsies Hematològiques, Cancer Research Program, imim-Hospital del Mar, Barcelona, Spain., Foot N; Viapath Genetics laboratories, Guys Hospital, London, UK., Jeffries S; West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, UK., Martin K; Department of Cytogenetics, Nottingham University Hospital, Nottingham, UK., O'Connor S; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK., Schoumans J; Oncogénomique laboratory, Hematology department, Lausanne University Hospital, Vaudois, Switzerland., Talley P; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK., Telford N; Oncology Cytogenetics Service, The Christie NHS Foundation Trust, Manchester, UK., Stioui S; Laboratorio di Citogenetica e genetica moleculaire, Laboratorio Analisi, Humanitas Research Hospital, Rozzano, Milan, Italy., Zemanova Z; Prague Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic., Hastings RJ; GenQA, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK. Ros.Hastings@ouh.nhs.uk.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2019 Aug; Vol. 33 (8), pp. 1851-1867. Date of Electronic Publication: 2019 Jan 29.
DOI: 10.1038/s41375-019-0378-z
Abstrakt: Cytogenomic investigations of haematological neoplasms, including chromosome banding analysis, fluorescence in situ hybridisation (FISH) and microarray analyses have become increasingly important in the clinical management of patients with haematological neoplasms. The widespread implementation of these techniques in genetic diagnostics has highlighted the need for guidance on the essential criteria to follow when providing cytogenomic testing, regardless of choice of methodology. These recommendations provide an updated, practical and easily available document that will assist laboratories in the choice of testing and methodology enabling them to operate within acceptable standards and maintain a quality service.
Databáze: MEDLINE
Externí odkaz: